New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

While more companies are using real-world data (RWD) and real-world evidence (RWE) in research, there are still barriers that continue to plague its uptake. One of the main barriers for companies ...

In the last decade, the volume of clinical trial data has surged, presenting unprecedented challenges for sponsors and contract research organizations (CROs). The task of collecting, cleaning, ...

In today's fast-paced and ever-evolving landscape of clinical trials, the ability to efficiently analyze and visualize data has become paramount. The vast amounts of data generated from these trials ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...

Transforming Clinical Research: assisTek's Innovative New Platform Raises the Bar for Data Collection and Patient Impact DOYLESTOWN, PA / ACCESSWIRE / March 26, 2024 / assisTek, a leading innovator in ...

This analysis is by Bloomberg Intelligence Industry Analyst Andrew Galler and Senior Associate Analyst Jack Maltby. It appeared first on the Bloomberg Terminal. Clinical trials represent a significant ...

Lindus Health is set to partner with the Clinical Data Interchange Standards Consortium (CDISC) to leverage AI in accelerating the development of standardised biomedical concepts for clinical trials.

Please provide your email address to receive an email when new articles are posted on . Use of decentralized elements in cancer clinical trials did not have long-term negative effects on data quality.

U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., and other senior FDA officials recently published a “Special Communication” in JAMA describing FDA’s concerns with the use of ...